Overview

Capecitabine Induced Hand And Foot Syndrome

Status:
Not yet recruiting
Trial end date:
2023-11-01
Target enrollment:
Participant gender:
Summary
The aim of the study is to evaluate the efficacy of using combination of Urea-based cream (CARBAMIDE®) and topical diclofenac (VOLTAREN®) Emulgel 1% for improving the incidence of Hand-foot syndrome in histologically proven breast cancer Egyptian patients receiving single agent chemotherapy Capecitabine (XELODA ®) and Its effect on improving patients' quality of life.
Phase:
Phase 2
Details
Lead Sponsor:
German University in Cairo
Collaborator:
Cairo University
Treatments:
Diclofenac